| S7827 |
4-Hydroxytamoxifen (Afimoxifene)
|
4-Hydroxytamoxifen (Afimoxifene) is the active metabolite of tamoxifen and a selective estrogen receptor (ER) modulator that is widely used in the therapeutic and chemopreventive treatment of breast cancer. It activates on-target modification frequency for intein-Cas9 variants.
|
-
Signal Transduct Target Ther, 2025, 10(1):97
-
Cell Death Differ, 2025, 10.1038/s41418-025-01514-7
-
Cell Rep, 2025, 44(5):115652
|
|
| S2638 |
NU7441 (KU-57788)
|
NU7441 (KU-57788) is a highly potent and selective DNA-PK inhibitor with IC50 of 14 nM. It also inhibits mTOR and PI3K with IC50 of 1.7 μM and 5 μM in cell-free assays, respectively, and reduces the frequency of NHEJ while increasing the rate of HDR following Cas9-mediated DNA cleavage.
|
-
Nat Cell Biol, 2025, 27(1):59-72
-
Trends Biotechnol, 2025, S0167-7799(25)00314-2
-
Nat Commun, 2025, 16(1):997
|
|
| S2775 |
Nocodazole
|
Nocodazole is a rapidly-reversible inhibitor of microtubule polymerization, also inhibits Abl, Abl(E255K) and Abl(T315I) with IC50 of 0.21 μM, 0.53 μM and 0.64 μM in cell-free assays, respectively. Nocodazole induces apoptosis.
|
-
Adv Mater, 2025, e17493.
-
Nat Commun, 2025, 16(1):7898
-
EMBO J, 2025, 44(22):6556-6597
|
|
| S8844 |
BRD0539
|
BRD0539 is a potent inhibitor of Streptococcus pyogenes Cas9 (SpCas9) with IC50 of 22 μM in an in vitro DNA cleavage assay.
|
-
Mol Cell, 2021, S1097-2765(21)00168-4
|
|
| S7046 |
Brefeldin A (BFA chemical)
|
Brefeldin A (BFA) is a lactone antibiotic and ATPase inhibitor for protein transport with IC50 of 0.2 μM in HCT 116 cells, induces cancer cell differentiation and apoptosis. It could also improve the HDR(homology-directed repair) efficiency and be an enhancer of CRISPR-mediated HDR. Brefeldin A is also an inhibitor of autophagy and mitophagy.
|
-
Protein Cell, 2025, pwaf020
-
Cancer Commun (Lond), 2025, 10.1002/cac2.70036
-
J Integr Plant Biol, 2025, 67(8):2229-2244
|
|
| S7742 |
SCR7
|
SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
|
-
Mol Ther, 2025, S1525-0016(25)00650-1
-
bioRxiv, 2025, 2025.08.05.668752
-
Nucleic Acids Res, 2024, 52(22):13757-13774
|
|
| S2579 |
Zidovudine
|
Zidovudine (ZDV, Azidothymidine, NSC 602670) is a nucleoside analogue reverse transcriptase inhibitor, used to treat HIV. This compound could decrease the HDR efficiency and decrease CRISPR-mediated sequence-specific genome knockin events while increaseing knockout efficiency.
|
-
Nat Commun, 2024, 15(1):2716
-
Nat Commun, 2024, 15(1):9321
-
J Immunother Cancer, 2024, 12(11)e009805
|
|
| S7974 |
L755507
|
L-755,507 is characterized as a potent and selective β3 adrenergic receptor partial agonist with EC50 of 0.43 nM. It is also recently identified to enhance CRISPR-mediated homology-directed repair (HDR) efficiency in human induced pluripotent stem cells (iPSCs) and other cell types.
|
-
Nucleic Acids Res, 2024, 52(22):13757-13774
-
Front Cell Dev Biol, 2023, 11:1276890
-
bioRxiv, 2023, 10.1101/2023.10.03.560773
|
|
| S8234 |
RS-1
|
RS-1 is a RAD51-stimulatory compound, which increases the DNA binding activity of RAD51. It is an HDR(homology-directed repair) enhancer that enhances Cas9- and TALEN-mediated knock-in efficiency in rabbit embryos both in vitro and in vivo.
|
-
Sci Bull (Beijing), 2025, S2095-9273(25)00865-5
-
Functional & Integrative Genomics, 2025, 180
-
Funct Integr Genomics, 2025, 25(1):180
|
|
| S0102 |
L 189
|
L 189 is a novel human DNA ligase inhibitor with IC50 of 5 μM, 9 μM and 5 μM for hLigI, hLigIII and hLigIV, respectively. This compound inhibits base excision repair (BER) and non-homologous end joining (NHEJ). It specifically sensitizes cancer cells to DNA damage.
|
|
|